NuVasive (Nasdaq:NUVA) - Aktienkurs, Nachrichten und Analyse

NUVA Aktienübersicht

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery.

NUVA grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	3/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	3/6
Dividenden	0/6

Belohnungen

47.4% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 46.22% pro Jahr

In diesem Jahr profitabel geworden

Analysten sind sich einig, dass der Aktienkurs um 23.3%

Risikoanalyse

Die Verschuldung ist durch den operativer Cashflow nicht gut gedeckt

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

NuVasive, Inc. Wettbewerber

CONMED

NYSE:CNMD

US$2.1b

Integra LifeSciences Holdings

NasdaqGS:IART

US$2.3b

LeMaitre Vascular

NasdaqGM:LMAT

US$1.8b

InMode

NasdaqGS:INMD

US$1.5b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für NuVasive
Historische Aktienkurse
Aktueller Aktienkurs	US$39.75
52-Wochen-Hoch	US$49.53
52-Wochen-Tief	US$35.17
Beta	1.07
11 Monat Veränderung	-0.63%
3 Monate Veränderung	0.84%
1 Jahr Veränderung	-8.30%
33 Jahre Veränderung	-22.24%
5 Jahre Veränderung	-42.71%
Veränderung seit IPO	248.68%

Aktuelle Nachrichten und Updates

Recent updates

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Apr 18

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

Jan 24

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Dec 31

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Dec 05

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Nov 13

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

Aug 03

NuVasive: Industry Tailwinds More Than Fairly Priced

Jun 13

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jun 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

May 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Apr 20

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

Mar 30

NuVasive's Turnaround Story Needs A Boost From Better Results

Mar 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Dec 28

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Dec 02

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Nov 11

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Oct 21

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Sep 29

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

Aug 18

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

Aug 12

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Jul 27

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Jun 17

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

May 30

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

May 12

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Mar 30

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Mar 09

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

Feb 16

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jan 26

NuVasive stock gains on study results of its X360 surgery approach

Jan 06

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Jan 05

Aktionärsrenditen

	NUVA	US Medical Equipment	US Markt
7D	1.5%	0.6%	0.5%
1Y	-8.3%	0.03%	23.9%

Rendite im Vergleich zur Industrie: NUVA unter dem Niveau der Branche US Medical Equipment, die im vergangenen Jahr eine Rendite von 5.5% erzielte.

Rendite vs. Markt: NUVA hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is NUVA's price volatile compared to industry and market?
NUVA volatility
NUVA Average Weekly Movement	3.8%
Medical Equipment Industry Average Movement	7.8%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

Stabiler Aktienkurs: NUVA hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: NUVADie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1997	3,000	Chris Barry	www.nuvasive.com

NuVasive, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von NuVasive im Vergleich zum Marktanteil des Unternehmens?
NUVA grundlegende Statistiken
Marktanteil	US$2.08b
Gewinn(TTM)	US$28.45m
Umsatz(TTM)	US$1.23b

73.3x

Kurs-Gewinn-Verhältnis

1.7x

Kurs-Umsatz-Verhältnis

Ist NUVA zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
NUVA Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$1.23b
Kosten der Einnahmen	US$347.50m
Bruttogewinn	US$878.73m
Sonstige Ausgaben	US$850.28m
Umsatz	US$28.45m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.54
Bruttomarge	71.66%
Nettogewinnspanne	2.32%
Schulden/Eigenkapital-Verhältnis	89.1%

Wie hat sich NUVA auf lange Sicht entwickelt?

Historische Performance und Vergleiche

NUVA Aktienübersicht

Belohnungen

Risikoanalyse

NuVasive, Inc. Wettbewerber

NYSE:CNMD

US$2.1b

NasdaqGS:IART

US$2.3b

NasdaqGM:LMAT

US$1.8b

NasdaqGS:INMD

US$1.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Recent updates

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Provides Sales Guidance for the Full Year 2023

NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023

NuVasive, Inc. Announces Resignation of Marc Rosenbaum as Vice President, Corporate Controller and Chief Accounting Officer

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Provides Sales Guidance for the Year 2023

NuVasive, Inc., Annual General Meeting, Jun 09, 2023

NuVasive, Inc. to Report Q1, 2023 Results on May 10, 2023

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

CEO & Director exercised options and sold US$491k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

NuVasive, Inc. to Report Q4, 2022 Results on Feb 22, 2023

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Price target decreased to US$49.25

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Year 2022

NuVasive, Inc. Launches Tube System and Excavation Micro for Posterior Spine Surgery

NuVasive, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$56.00

Nuvasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive, Inc. Announces Departure of Massimo Calafiore as Executive Vice President and Chief Commercial Officer, Effective August 31, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive, Inc. to Report Q2, 2022 Results on Aug 03, 2022

NuVasive: Industry Tailwinds More Than Fairly Priced

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive, Inc. Announces Management Changes

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Now 21% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive, Inc. to Report Q1, 2022 Results on May 04, 2022

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc., Annual General Meeting, May 11, 2022

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Full year 2021 earnings: EPS exceeds analyst expectations

NuVasive, Inc. Provides Earnings Guidance for the Full Year 2022

NuVasive, Inc. to Report Q4, 2021 Results on Feb 23, 2022

NuVasive, Inc. Appoints Andrew C. Morton as Senior Vice President and Chief Human Resources Officer, Effective February 7, 2022

Nuvasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Thoracolumbar Interbody Portfolio

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Price target decreased to US$66.19

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Erträge & Einnahmen